Introduction
Influenza viruses are responsible for a high proportion of respiratory disease with infection caused by influenzaA or B, or both, recurring each winter (Nicholson and Wiselka, 1991) .The recent outbreak of influenzaA in 1989-90 in the UK was a reminder of how serious the disease can be, since approximately 26000 deaths were associated directly or indirectly with the outbreak (Curwen et al. 1990 ). Deaths attributed directly to the virus were not confined just to the elderly but occurred in all age groups inclUding babies (personal communication, PHLS) . This outbreak exemplified some ofthe problems associated with the use of vaccines under epidemic situations and further confirmed the need for an effective anti-influenza agent.
The influenza inhibitor amantadine which has been studied extensively in clinical trials (Hoffman, 1973) is licensed for use in the prophylaxis and treatment of influenza. However, this compound and the closely related rimantadine have severe limitations in that the compounds are only effective against influenza A (Hoffman. 1973 ) and that resistant virus can emerge rapidly during treatment (Hayden et al., 1989) . Further, resistant virus has been shown to give rise to disease in humans (Hayden et aI., 1989) . Other agents include the nucleoside analogue ribavirin which has activity against both influenza A and B in vitro and in vivo (Sidwell et aI., 1972) but proved disappointing in clinical trials (Smith et aI., 1980) . One further compound, 1,3,4-thiadiazol-2-Ylcyanamide which has been reported to possess both influenza A and B inhibitory activity (Colacino et el., 1990) is undergoing clinical evaluation. However, it has been observed that this compound lacks specificity (Hayden et aI., 1990) which casts doubt on the clinical potential of the compound. In view of these data, there is a requirement for an effective inhibitor of influenza A and B which will not generate rapidly resistant virus.
We have synthesized a number of 2'-deoxy-2'-fluororibosides ( Fig. 1 ) which have shown significant inhibitory activity against influenza A in MOCK cells (Tuttle et ei., 1992) . In this study we evaluated the anti-influenza activity of this series of 2'-deoxy-2'-fluororibosides further against different strains of influenza A and B in a variety of cell culture systems and in vivo, in the mouse.
Results

Comparison of the anti-influenza activity of the 2'fluororiboside analogues in CEF celts, MOCK cel/s and in the mouse model
For primary evaluation of anti-influenza activity, plaque reduction with AlSweden/3/50[H 1 N 1 ] in MOCK cells was used, followed by assessment of activity in vivo, monitored by reduction in virus growth in the mouse lung. In addition, comparisons were made with yield reduction assays in primary CEF cells using the recombinant strain ··,1 I AlX31. All the data from these assays has been tabulated and, for convenience, the compounds have been divided into three groups based on compound structure (Table 1) . From group A, the pyrimidine containing 2'~fluororibo sides, only the cytosine analogue (2' -fluorodCyt) is active with similar IC 50's against both viruses in the two cell lines. However, in vivo, this analogue was inactive presumably due to deamination to 2'-fluorodUra.
The purine containing 2'-f1uororibosides have been divided into 2 groups. Group S, consisting of 2'-fluororibosides of purines lacking a 2-substituent, which might be metabolized in vivo and possibly in cell culture firstly to the adenosine and/or to the inosine analogue. All of these analogues showed high activity with IC 50's down to 0.9 f-LM against AlX31 in CEF cells and significant reductions (1-2 log10units) in growth of AlSweden in the mouse lung, but little or no activity against AlSweden in MOCK cells. This low activity in MOCK cells is possibly due to metabolism or poor cell uptake of the compounds in this cell line.
Group C, consisting of 2'-fluororibosides of purines with a 2-substituent which might be converted to 2'-fluo-rodGuo in cell culture and in vivo. These analogues, with the exception of the 2-amino analogue, proved to be the most active against X31 in CEF cells with IC 50's ranging from 0.1 to 2.9 f-LM and against AlSweden in MOCK cells with IC 50's in the range 16-36 f-LM. However, in vivo, reductions in virus growth were similar to or only slightly greater than those seen with the Group S 2'-fluororibosides, or with amantadine, or ribavirin. Although the pathogenesis of pneumonia and death in the mouse is complex, virus tit res correlate with the severity of symptoms, and therefore these compounds should have a beneficial effect on the disease syndrome. A small study was carried out to establish whether 2'-fluorodGuo would have an effect on survival of mice (Cm) infected with influenza AlSweden. From Fig. 2 it can be seen that indeed 2'-fluorodGuo significantly increased the number of mice surviving and their survival times, but appeared marginally less active than amantadine, although this difference was not statistically significant. No toxicity was observed with * The concentrations of compound required to inhibit virus by 50% (IC50) was determined by plaque reduction using 4-5 compound concentrations in duplicate with AlSweden in MOCK cells, and by yield reduction using 4-5 compound concentrations in triplicate with A/X31 in CEF cells. Results from individual assays or means ± SO for 5 assays are shown.
t Virus titres in mouse lungs 24h after infection with AlSweden were titrated by plaque formation in MOCK cells. Compounds were administered intraperitoneally 4h before and 4 and 20h after infection at 100mg kg-1 dose:". , The concentration of compound required to inhibit cell growth by 50% (CC50). Results from 1 or 2 assays. I 2'-Oeaxy-2'-fluararibaside inhibitors of influenza 283 Table 3 . Antagonism of 2'-fluorodGuo and 2'-fluorodCyt anti-influenza activity by different nucleosides.
parainfluenza virus 1 (Sendai) was also sensitive when tested in CEF cells (IC so 1.7I-LM).
Although all the influenza strains tested have similar sensitivities to 2'-fluorodGuo, there was a marked difference in activity between the two cell lines. Similarly when effects on cell growth were compared there was a difference, in MOCK cells the CC so for 2'-fluorodGuo was 437I-LM whereas in CEF cells the CC so was 171-LM. However, the therapeutic ratio was similar in both cell lines, within the range 20-200. This suggests that the compound is either differentially taken up by these cell lines or metabolized differently. To study this further [14C]2'-fluorodGuo was synthesized and used in uptake studies in both cell lines. Table 2 show that all strains tested were sensitive to the compound with a range of ICso'sfrom 0. Metabolism of2'fluorodGuo in MOCK and CEF cells HPLC analysis of MOCK and CEF cells treated with 50 I-LM radioactive compound for 24 h revealed significant differences in 2'-fluorodGuo-triphosphate levels formed in these two cell lines, 1.6I-LM. (MOCK) and 116I-LM (CEF) which correlated with anti-influenza activity. No differences were seen in the triphosphate levels between infected and uninfected cells (data not shown) indicating that cellular enzymes are involved in conversion of the compound to its active form, the triphosphate. Further studies using a range of nucleosides to try to reverse the influenza inhibition revealed that only deoxyribosides would reverse the activity of 2'-fluorodGuo and that deoxy-cytidine was much more effective than cytidine against 2'-fluorodCyt (seeTable 4)suggesting that cellular enzymes were recognizing the 2'-fluoro-sugar as a deoxyriboside. Further, in vitro studies with purified calf thymus 6 Development of resistance to 2'-fluorodGuo
Attempts were made to try to develop resistant virus by passing the X31 influenza recombinant in increasing concentrations of 2'-fluorodGuo from 1/LMto 5/LM over 10 passes in CEF cells. Virus was plaque purified twice and a stock grown up in eggs. From yield reduction assays in CEF cells the IC 50 of virus passed in the presence of compound was 3/LM compared with 0.6/LMfor wild type, showing a shift of fivefold in sensitivity. Further attempts to produce virus with greater resistance were without success.
ciliary activity, giving more than a 4 log10 unit reduction in virus growth at 20 /LM on day 3 (Fig. 3 ). This indicates that the enzymes required to phosphorylate 2'-fluorodGuo are present in the target organ in man. 2'-fluorodCyt was found to be equally active (data not shown). (0). Tracheal cultures were prepared and incubated at 37"C for 24 h and checked for ciliary activity before infection with 1000 TCI0 50 of A/Eng/40/83 (H3N2). With treated cultures compounds were added with virus. Medium was removed for virus titrations on the days indicated and fresh medium was added, with compound where appropriate. Compound controls to check for adverse effects on ciliary activity were also included.
5 Table 4 . Comparison of K'm constants of deoxyribosides and 2'-f1uororibosides for calf thymus deoxycy1idine kinase .• deoxycytidine kinase revealed that the 2'-fluororibosides were good substrates for this enzyme (Table 5) .
• The enzyme was purified and assayed as previously described (Krenitsky at al., 1976) . Kinetic constants (±standard error) were determined from a minimum of seven initial velocity measurements over a range of substrate concentrations which spanned the K'm value. The kinetic data were analysed as previously described (Cleland, 1979) . t V'max values are expressed as a percentage of the V'max for dGuo phosphorylation (20 mols rnln" mg-1 ) . * Published values (Krenitsky at al., 1976) .
Anti-influenza activity in human tracheal cultures
Variations in phosphorylation and anti-influenza activity in different cell lines indicated that further evaluation was necessary in the human target organ. Experiments were designed to compare the activity of both 2'-fluorodCyt and 2'-fluorodGuo with amantadine in human tracheal cultures. Virus titres were monitored on days 1,2,3, and 7, in the presence of 2/LM and 20/LM compound concentrations. Surprisingly, amantadine only gave low level activity at 20/LM in this assay, while 2'fluorodGuo was active at both 2 and 20/LM without causing adverse effects on Exp.
Mice were infected with approximately 10 L0 5 0 of virus by aerosol and treated orally 0.5, 4, and 20 h after infection at 40mg kg-1 dose ". Mice were sacrificed 24h after infection and 10% lung suspensions titrated in MOCK cells. NO = not done.
Comparison of the 2'-fluororibosides with amantadine and ribavirin in the mouse pneumonia model
For initial evaluation of activity in vivo, compounds were administered before infection with virus to maximize sensitivity, in a system where viruses have been adapted to grow very rapidly giving rise to lethal infection. With this treatment regime little difference was seen between the activity of the different analogues, or with amantadine and ribavirin. However, for influenza therapy in humans a compound is required which will be active orally when taken after infection. We have shown previously that using highly adapted viruses (30 passes in the mouse lung), delaying treatment to 4 h after infection with amantadine or ribavirin results in little or no inhibition of 24h peak virus titres. Therefore, further comparisons were made in the mouse model between 2' -fluorodGuo and 2' -fluorodAdo ,with amantadine and ribavirin against both influenza A and B strains, where oral treatment was commenced 30 min after infection. Under this treatment regime (see Table 5 ) 2'-fluorodGuo was considerably jpore active against influenza A than either 2'-fluorodAfi1P or amantadine (P < 0.01), which showed similar actl~fty. Ribavirin was not active when given after infection against the influenza A strain, but showed some activity against the B strain.
However, both 2'-fluorodGuo (P < 0.001) and 2'-fluoro-dAdo (P < 0.01) were significantly more effective than ribavirin against influenza B. The increased activity seen with 2'-fluorodGuo in contrast to the other compounds, under this treatment regime, probably reflects differences in pharmacokinetics of the compounds. No signs of toxicity were observed with any of the compounds tested. Further in vivo metabolism and toxicity studies with 2'-fluorodGuo are underway.
Discussion
The 2'-fluororibosides are an interesting series of compounds showing high level inhibitory activity against influenza A and B strains and against parainfluenza 1, the only parainfluenza virus tested. Low level activity was observed with some analogues against Respiratory Syncytial virus (data not shown) but viruses from other respiratory virus groups, namely Rhinovirus and Coronavirus were not sensitive. Some of the 2'-fluororibosides have been synthesized previously (Codington et aI., 1964; lkehara and lmura et et., 1981) and 2'-fluorodCyt has been reported to possess anti-herpes simplex virus types 1 and 2, pseudorabies and equine abortion virus activity (Wohlrab et al., 1985) but there are no previous reports of activity against influenza viruses. We have also observed low level activity with some analogues against herpes viruses including Varicella zoster virus and Cytomegalovirus but structure activity relationships as seen with the influenza viruses were not obtained.
2'-Deoxy-2'-fluororiboside inhibitors of influenza 285
Three-structural types within the series show activity, 2'-fluorodCyt, 2'-fluorodAdo and analogues, and 2'-fluo-rodGuo and analogues, each of which possess slightly different sensitivity profiles. With the pyrimidine analogues, it was surprising that the 2'-fluorodUra was inactive against an RNA virus, but this is due at least in part to lack of phosphorylation by cellular enzymes. Although showing good activity in tissue culture, the cytidine analogue was inactive in vivo, presumably due to deamination to the uridine analogue. From the purine analogues, 2'-fluorodGuo proved the most active in tissue culture and this was later confirmed in vivo in the mouse model. For in vivo evaluation of compounds we chose to look directly at effects on virus growth in the lungs rather than at signs of infection, such as lung consolidation or death, since compounds without anti-influenza activity may indirectly affect the outcome of disease in mice (Groupe et aI., 1952) . Previously, we have shown that death is related to lung virus titres (Tisdale and Bauer, 1977) and, in influenza studies in humans, severity of symptoms are related to nasal virus titres (Murphy et aI., 1973) . Thus quantitative comparisons were obtained in the mouse which demonstrated that 2'-fluorodGuo was more effective than both amantadine and ribavirin when administered after infection. The higher activity seen with 2'-fluorodGuo when given orally after infection in contrast to pretreatment by intraperitoneal inoculation was surprising and will be studied further by looking at compound plasma levels and cellular triphosphates levels in the mouse. In addition, as predicted from the virus data, we confirmed that 2'-fluo-rodGuo would protect mice from a lethal infection of influenza. This data together with the broader spectrum of anti-influenza activity and the superior activity seen in the human target organ over amantadine suggest that these compounds have potential for use in humans.
Variations in activity of the compounds were observed between different cell lines which, when examined further revealed that the compounds were phosphorylated by cellular enzymes. Reversal of activity by different nucleosides, and later confirmed using isolated calf thymus deoxy-cytidine kinase, demonstrated that the 2' -fluororlbosides were recognized as deoxyribosides. The data from this study suggests that the triphosphates of the 2' -fluororibosides inhibit replication of influenza viruses and act as ribonucleotide analogues. Further studies to elucidate the mechanism of action of these inhibitors have been undertaken and will be discussed in a later paper.
Attempts to produce resistant virus were only partially successful suggesting that the mechanism of inhibition was virus specific, and that these inhibitors are targeting an essential function of virus growth, possibly, since they are nucleoside analogues the viral polymerase complex. These studies are encouraging in that they indicate that development of resistance with this type of inhibitor may not be a problem as seen with amantadine. Thus these compounds possess three important attributes for a potential influenza treatment, namely, high potency, a spectrum of activity which covers influenza A and B strains, and a mechanism of action which should not rapidly generate resistant virus.
Materials and Experimental procedures
Compounds
Purine 2' -deoxy-2'-fluororibosides were synthesized by enzymatic transfer (Tuttle et al., 1992) using 2'-deoxy-2'-fluorouridine (2'-fluorodUra) synthesized as described (Codington et al., 1964) , as donor. Other pyrimidine analogues were synthesized by published methods (Codington et el., 1964) . Amantadine hydrochloride and ribavirin were obtained from Sigma Chemical Company (St Louis, MO). Compounds were either dissolved in water or in DMSO and then diluted in culture medium for cell culture assays and for in vivo assays in 1% Triton X100 as solutions or suspensions depending on solubility. 2'-deoxy-2'fluoro (2-14)guanosine (2'-fluorodGuo), synthesized at Wellcome Research Laboratories, RTP, USA, had a specific activity of 63mCi rnmor'.
Cells and viruses
Primary chick embryo fibroblasts (CEF) were prepared from 10-day-old fertile hens eggs. Madin Darby Canine kidney cells (MDCK) were obtained from the American Type Culture Collection (CCL34). Influenza A and B strains were obtained generally from the Influenza Reference Laboratory, Mill Hill. The two (H3N2) recombinant viruses are crosses between AlPuerto Rico/8/34 and AlAichi/2/68 (X31) and AlEngland/939/69 (7a) and were received from E. D. Kilbourne, New York and C. Sweet, Birmingham, UK, respectively. Virus stocks were prepared in the allantoic cavity of 10-day-old fertile hens eggs and infected allantoic fluid stored at -70°C for use in tissue culture assays. For in vivo mouse work, mouse-adapted viruses were used (Tisdale and Bauer, 1975) as 10% infected lung suspensions.
Evaluation of anti-influenza activity in cell culture
Compounds were evaluated for anti-influenza activity by plaque reduction in MDCK cells (Hayden et al., 1980) and by yield reduction in CEF cells. In the latter tests, cells were infected with 10 TCID so of virus and virus yields titrated by haemagglutination after 48h incubation at 37"C.
Evaluation of inhibition of cell growth
The effect of 2' -fluorodGuo on dividing cells was determined in 96 well microtitre plates seeded at 10 s cells well-1 for CEF cells and in 24-well plates at 2 x 10 4 cells well-1 for MDCK cells. Compound was included in the growth medium at various concentrations and cell growth compared with untreated controls over 4 days incubation (CEF 2-3 cell doublings; MDCK 3-4 cell doubllnqs), Cell viability was quantified spectrophotometrically after adding the tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTI) which is metabolized by viable cells to the blue Formazan derivative, and cell solubilization using acidified isopropanol. Results were expressed as CC so , the concentration that inhibits cell growth by 50%.
Evaluation of anti-influenza activity in the mouse pneumonia model
For in vivo studies, mouse-adapted AlSweden/50 (H1N1) and B/Lee/44 were used to infect mice (BALB.C, 18-20g) by aerosol. For initial evaluation of activity, mice (5/treatment group/cage) were treated by intra-peritoneal inoculation 4 h before infection and 4 and 20 h after infection. In evaluation of therapeutic activity mice were dosed orally 0.5, 4 and 20h after infection. Mice were sacrificed at 24h at the time of peak virus growth (Tisdale and Bauer, 1977) , the lungs removed and individual lung samples (10% suspensions in 10% Tryptose Phosphate Broth in PBS) titrated by plaquing in MDCK cells.
For mortality studies, mice (CD1 18-20 g) were infected by intranasal inoculation with 10 LD so of virus and treated subcutaneously 4 h before and 4 h after infection and then twice daily for 5 days. Deaths were recorded to the nearest half day over a 20 day observation period. Statistical analysis to compare treatment groups, assuming no cage effects, were made using analysis of variance (virus lung titre data) and by Logrank tests (mortality data), where P < 0.05 was considered significant.
Nucleotide analysis of different cell extracts by HPLC
Cell cultures were incubated at 37"C with medium containing 14[C]-labelled 2' -fluorodGuo for 24h. The medium was removed, cells trypsinized, washed with PBS and extracted with 9 volumes of cold 3.5% perchloric acid. Extracts were analysed by HPLC as described (Elion et al., 1977) .
Evaluation of anti-influenza activity in Human Embryonic Tracheal cultures
Squares of human tracheal epithelium were prepared (Tyrrell and Hoorn, 1965) and incubated in maintenance medium for 24 h. Cultures were checked for ciliary activity and infected with 1000 TCID so of the clinical isolate AlEngland/40/83(H3N2). Cultures in duplicate were treated with test compounds added with virus, and virus growth monitored by taking supernatant and titrating in MDCKcelis.
